Fiscal Year 2026 Financial Results Announcement ｜ Revenue of JPY 2.46 billion, Operating Profit of JPY 210 million

Overview of Financial Results

Niitaka achieved sales of JPY 24,619 million (YoY +3.8%) and operating profit of JPY 2,118 million (10.1% increase) for the fiscal year ending May 2026. The Chemical segment remained robust due to steady demand in the food service industry and sales expansion of high-value-added products. Meanwhile, the Healthcare segment experienced decreased revenue amid declining domestic and international demand but secured profits through cost reductions. The company forecasts sales of JPY 27.5 billion and net profit of JPY 1.28 billion for the current period, continuing to focus on profit sharing and business expansion.

Future Outlook and Impact on Shareholders

Going forward, Niitaka will respond to external environmental changes while maintaining profitability in the Chemical segment supported by steady demand. The Healthcare segment will aim for long-term growth through overseas expansion and new product development. The dividend will be increased to JPY 39, with a planned total of JPY 84 for interim and year-end payments in the next period. The company emphasizes shareholder return and promotes a balanced approach to capital policy and business strategy.